Program
sacituzumab drozuntecan
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by DualityBio.
Furthest: phase 2, since Jun 14, 20222 company-led studies, 2 open or runningNext primary completion: Aug 13, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| DualityBio | 22 open or running | phase 2since Jun 14, 2022 | Jun 14, 2022 | Aug 13, 2027phase 2 · NCT05438329 |
Also a collaborator on its studies: BioNTech.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 14, 2022First study: phase 2 study in Advanced Solid TumorFirst studyNCT05438329 · 1,123 enrolled · United States, China, Puerto Rico
- Apr 9, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06953089 · 750 planned · United States, Australia, China and more
Ahead
- Aug 13, 2027Primary completion: phase 2 study in Advanced Solid TumorNCT05438329
- Jun 30, 2030Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06953089
TargetBeta
TACSTD2 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) covalently ”NCIt, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab govitecanrule | Gilead Sciences | phase 4 | 30 |
| sacituzumab tirumotecan | Merck | phase 3 | 50 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 28 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06953089Squamous Cell Carcinoma of Head and Neck · United States, Australia, China and more | 2 | Recruiting | Jun 30, 2030 | 750 |
| NCT05438329Advanced Solid Tumor · United States, China, Puerto Rico | 2 | Active, not recruiting | Aug 13, 2027 | 1,123 |
How it is read
Names in the registry
- “DB-1305/BNT325”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.